Amarin reported $659.81M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amarin USD 659.81M 10.31M Sep/2025
AstraZeneca USD 114.46B 2.03B Sep/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
GlaxoSmithKline GBP 61.34B 2.08B Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025